PathScan® Signaling Nodes Multi-Target Sandwich ELISA Kit #7272
- ELISA+
Inquiry Info. # 7272
Please see our recommended alternatives.
Product Specifications
| REACTIVITY | H M |
Application Key:
- ELISA+-ELISA and/or ELISA-like Assays
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Description
Antibodies in kit are custom formulations specific to kit.
*See companion products.
Protocol
Specificity / Sensitivity
Species Reactivity:
Background
MEK1 and MEK2 are dual-specificity protein kinases that function in a mitogen activated protein kinase cascade controlling cell growth and differentiation. Activation of MEK1 and MEK2 occurs through phosphorylation of serine 217 and serine 221 by Raf-like molecules. MEK activates p44 and p42 MAP kinase (8-10).
p38 MAP kinase (MAPK) participates in a signaling cascade controlling the cellular response to pro-inflammatory cytokines and a variety of cellular stresses. MKK3, MKK6 and SEK (MKK4) activate p38 MAP kinase by phosphorylation at Thr180 and Tyr182 (11-14).
The Stat3 transcription factor is an important signaling molecule for many cytokines and growth factor receptors. Stat3 is activated by phosphorylation at Tyr705, which induces dimerization, nuclear translocation and DNA binding (15,16).
Transcription factors of the nuclear factor κB (NF-κB)/Rel family play a pivotal role in inflammation, stress and immune responses. There are five family members in mammals: RelA/p65, c-Rel, RelB, NF-κB1 (p105/p50) and NF-κB2 (p100/p52). These proteins function as dimeric transcription factors. In unstimulated cells, NF-κB/Rel proteins are sequestered in the cytoplasm and inhibited by the IκB proteins. NF-κB-activating agents induce phosphorylation of IκB's, targeting them for degradation and thereby releasing the NF-κB/Rel complexes. Active NF-κB/Rel complexes are further activated by phosphorylation (17-20).
- Kim, D. and Chung, J. (2002) J Biochem Mol Biol 35, 106-15.
- Zdychová, J. and Komers, R. (2005) Physiol Res 54, 1-16.
- Song, G. et al. J Cell Mol Med 9, 59-71.
- Manning, B.D. and Cantley, L.C. (2007) Cell 129, 1261-74.
- Alessi, D.R. et al. (1996) EMBO J 15, 6541-51.
- Sarbassov, D.D. et al. (2005) Science 307, 1098-101.
- Jacinto, E. et al. (2006) Cell 127, 125-37.
- Alessi, D.R. et al. (1994) EMBO J 13, 1610-9.
- McKay, M.M. and Morrison, D.K. (2007) Oncogene 26, 3113-21.
- Pearson, G. et al. (2001) Endocr Rev 22, 153-83.
- Raingeaud, J. et al. (1995) J Biol Chem 270, 7420-6.
- Raman, M. et al. (2007) Oncogene 26, 3100-12.
- Zarubin, T. and Han, J. (2005) Cell Res 15, 11-18.
- Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
- O'Shea, J.J. et al. (2002) Cell 109 Suppl, S121-31.
- Kaptein, A. et al. (1996) J Biol Chem 271, 5961-4.
- Ghosh, S. and Karin, M. (2002) Cell 109 Suppl, S81-96.
- DiDonato, J. et al. (1996) Mol Cell Biol 16, 1295-304.
- Sakurai, H. et al. (1999) J Biol Chem 274, 30353-6.
- Mattioli, I. et al. (2004) J Immunol 172, 6336-44.
Alternate Names
Acute-phase response factor; ADMIO; ADMIO1; AKT; AKT serine/threonine kinase 1; AKT1; AKT1 kinase; AKT1m; APRF; CFC3; CMCU; CSAID-binding protein; Csaids binding protein; CSBP; CSBP1; CSBP2; CSPB1; cytokine suppressive anti-inflammatory drug binding protein; Cytokine suppressive anti-inflammatory drug-binding protein; DNA-binding protein APRF; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1; EXIP; FLJ20882; HIES; MAP kinase 14; MAP kinase kinase 1; MAP kinase MXI2; MAP kinase p38 alpha; MAP2K1; MAPK 14; MAPK/ERK kinase 1; MAPK14; MAPKK 1; MAPKK1; MAX-interacting protein 2; MEK 1; MEK1; MEL; MGC131774; MGC16063; MGC99656; Mitogen-activated protein kinase 14; mitogen-activated protein kinase kinase 1; Mitogen-activated protein kinase p38 alpha; MK14; MKK1; MP2K1; MXI2; NF-kappa-B p65delta3; NF-kappa-B transcription factor p65; NFkB-p65; NFKB3; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; p38; p38 MAP kinase; p38 mitogen activated protein kinase; p38-alpha; P38A; p38ALPHA; p38alpha Exip; p65; PKB; PKB alpha; PKB-ALPHA; PRKBA; PRKM14; PRKM15; PRKMK1; Protein kinase B; Protein kinase B alpha; protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1); Proto-oncogene c-Akt; RAC; rac protein kinase alpha; RAC-ALPHA; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; RELA; RELA proto-oncogene, NF-kB subunit; RELA/p65; RK; SAPK2A; serine-threonine protein kinase; Signal transducer and activator of transcription 3; signal transducer and activator of transcription 3 (acute-phase response factor); STAT3; stress-activated protein kinase 2A; TF65; Transcription factor p65; v-akt murine thymoma viral oncogene homolog 1; v-akt murine thymoma viral oncogene-like protein 1; v-rel avian reticuloendotheliosis viral oncogene homolog A; v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (p65)); v-rel reticuloendotheliosis viral oncogene homolog A (avian); v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, p65
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.